Abstract
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare form of hematologic malignancy characterized by lesions in subcutaneous fat associated with systemic symptoms. The standard treatment of the disease, currently, is not established, but CHOP or CHOP-like regimens are usually given. We report, herein, 4 cases of SPTCL diagnosed by histopathology and immunohistochemistry who were refractory to CHOP and/or ESHAP and/or fludarabine-based regimen, but showed rapid improvement within weeks after oral cyclosporin 4 mg/kg/day. Three sustained complete remission for the durations of 8 - 9 months off-treatments. T-cell receptor gene rearrangement revealed polyclonality in 3 cases and monoclonality in 1 case. Our data suggest the benefit of incorporating cyclosporin into the treatment regimen for SPTCL.
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cisplatin / therapeutic use
-
Cyclophosphamide / therapeutic use
-
Cyclosporine / therapeutic use*
-
Cytarabine / therapeutic use
-
Doxorubicin / therapeutic use
-
Etoposide / therapeutic use
-
Female
-
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Lymphoma, T-Cell, Cutaneous / drug therapy*
-
Male
-
Methylprednisolone / therapeutic use
-
Middle Aged
-
Panniculitis / pathology*
-
Prednisone / therapeutic use
-
Prognosis
-
Remission Induction
-
Skin Neoplasms / drug therapy*
-
Treatment Outcome
-
Vincristine / therapeutic use
Substances
-
Immunosuppressive Agents
-
Cytarabine
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclosporine
-
Cyclophosphamide
-
Cisplatin
-
Prednisone
-
Methylprednisolone
Supplementary concepts
-
CHOP protocol
-
ESAP protocol